TUCSON, Arizona, Aug. 24, 2015 /PRNewswire/ -- HSRx Group, an Arizona-based biopharmaceutical company, announced it is nearing completion of a clinical trial for its OTC acne treatment product, HSRx 2121. The trial is being conducted by Moore Clinical Research, Inc., an independent FDA-compliant Contract Research Organization with considerable experience in acne product testing. The fully randomized placebo-controlled trial compares the performance of HSRx's acne treatment product with that of a market-leading product and of a placebo. The six-week trial involves 90 subjects and focuses on alleviating facial acne and reducing redness and intensity of breakouts. Results will be announced in coming weeks.

"Acne is a disease that deals a heavy blow to the self-esteem of those affected," says Robert Gow, Executive Chairman of HSRx Group. "Acne is among the 10 most prevalent human diseases and recent studies show it has a huge, long-term psychological impact on many of the 80+% of teenagers and young adults affected by this disease."

"Current topical treatments are so harsh," Gow notes, "that a significant percentage of consumers discontinue their use before desired results are achieved. The medical community also knows that overuse of antibiotics generally is creating antibiotic-resistant superbugs, with horrific implications. A new, more effective next generation acne treatment is needed and our aim with this clinical trial is to demonstrate that the HSRx acne treatment product meets that need."

The global market for acne products is estimated at $3-4 billion, with significant expansion expected from growing middle-class populations in China and India. HSRx CFO Frank Parise observes, "As a parent of four children, I know teens and young adults want a faster-acting acne solution. They want the unsightly redness to quickly go away and they want a gentle treatment that reduces the severity of acne breakouts. We are confident that the HSRx acne treatment product will better fulfill these needs."

HSRx Group has developed a portfolio of next generation OTC drug products for many categories of common health conditions. Each product is subjected to independently-conducted clinical trials against a current market-leading product to demonstrate their ability to deliver superior treatment outcomes with reduced side effects. All HSRx OTC drug products utilize natural ingredients in formulations. HSRx out-licenses or joint-ventures its products with select marketing brands.

About HSRx Group

HSRx Group is a biopharmaceutical company developing next generation combination OTC and prescription drugs for the prevention and treatment of a broad group of disease conditions, including influenza, Alzheimer's, rheumatoid arthritis, solid tumor cancer, MRSA, type 1 diabetes, vascular dementia, stroke and others. Its technology integrates the disease-fighting nutrients of foods with select generic drugs to create unique pharmaceutical products with long patent lives. HSRx products equip healthcare providers with payer- and patient-friendly multiple-mechanism disease mitigation therapy options. More information is available at HSRxGroup.com.

Related Links

http://www.HSRxGroup.com

SOURCE HSRx Group